...
首页> 外文期刊>Molecular medicine reports >Differential expression of multidrug resistance-related proteins in adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human bladder cancer cell lines
【24h】

Differential expression of multidrug resistance-related proteins in adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human bladder cancer cell lines

机译:耐阿霉素(pumc-91 / ADM)和亲代(pumc-91)人膀胱癌细胞系中多药耐药相关蛋白的差异表达

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Multidrug resistance (MDR) is the major obstacle to bladder cancer chemotherapy. Several mechanisms have been implicated in the development of MDR, including extrusion of the drug by cell membrane pumps, associated with P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP); increased DNA damage repair, associated with topoisomerase II (Topo II); suppression of drug-induced apoptosis, associated with p53; and regulation of cancer cell growth, associated with vascular endothelial growth factor (VEGF). In the present study, the expression levels of these five markers were detected in an adriamycin (ADM) -resistant human bladder cancer cell line (pumc-91/ADM) and its parental cell line (pumc-91), in order to determine which marker is more important, or whether all of them participate in drug resistance. The expression levels of P-gp, MRP, Topo II, VEGF and p53 were measured in the two cell lines by reverse transcription-quantitative polymerase chain reaction, western blotting and immunohistochemistry. A significant increase in P-gp, MRP and VEGF, and a decrease in Topo II mRNA expression were detected in the pumc-91/ADM drug-resistant cell line compared with the pumc-91 cell line; however, no difference in p53 mRNA expression was detected between the cells. In pumc-91/ADM cells, the protein expression levels of P-gp and MRP were upregulated, whereas Topo II was significantly decreased. However, no marked differences in p53 or VEGF expression were detected between the two cell lines at the protein level. The cytoplasmic and cell membrane localization of P-gp and MRP, the cytoplasmic localization of VEGF, and the nuclear localization of p53 and Topo II were confirmed in the two cell lines. The present study detected increased P-gp and MRP, and reduced Topo II expression in pumc-91/ADM cells compared with pumc-91 cells; however, no difference was detected in p53 and VEGF expression between the cell lines. In conclusion, a significant upregulation of MRP and downregulation of Topo II were detected in the ADM-resistant human bladder cancer cell line (pumc-91/ADM) compared with in the parental cell line (pumc-91).
机译:多药耐药性(MDR)是膀胱癌化疗的主要障碍。 MDR的发展涉及多种机制,包括通过细胞膜泵将药物挤出,与P-糖蛋白(P-gp)和多药耐药相关蛋白(MRP)相关;与拓扑异构酶II(Topo II)相关的DNA损伤修复作用增强;抑制与p53相关的药物诱导的细胞凋亡;与血管内皮生长因子(VEGF)相关的癌细胞生长的调控。在本研究中,在抗阿霉素(ADM)的人膀胱癌细胞系(pumc-91 / ADM)和其亲本细胞系(pumc-91)中检测了这五个标记的表达水平,以确定哪个标记更重要,或者它们是否都参与耐药性。通过逆转录-定量聚合酶链反应,Western印迹和免疫组化检测了这两个细胞系中P-gp,MRP,Topo II,VEGF和p53的表达水平。与pumc-91细胞系相比,在pumc-91 / ADM耐药细胞系中检测到P-gp,MRP和VEGF显着增加,并且Topo II mRNA表达下降;然而,在细胞之间未检测到p53 mRNA表达的差异。在pumc-91 / ADM细胞中,P-gp和MRP的蛋白表达水平上调,而Topo II则明显降低。然而,在蛋白质水平上,在两种细胞系之间未检测到p53或VEGF表达的显着差异。在这两个细胞系中证实了P-gp和MRP的胞质和细胞膜定位,VEGF的胞质定位以及p53和Topo II的核定位。本研究检测到与pumc-91细胞相比,pumc-91 / ADM细胞中P-gp和MRP升高,并且Topo II表达降低。然而,在细胞系之间未检测到p53和VEGF表达的差异。总之,与亲本细胞系(pumc-91)相比,在抗ADM的人膀胱癌细胞系(pumc-91 / ADM)中检测到了MRP的显着上调和Topo II的下调。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号